Core Insights - Sotera Health Company has appointed Kenneth D. Krause as a new independent director to its Board of Directors, enhancing its governance and strategic capabilities [1][3] Group 1: Appointment of Kenneth D. Krause - Kenneth D. Krause has extensive experience as a public company chief financial officer, having served at Rollins, Inc. and MSA Safety Incorporated, where he led initiatives that improved growth and profitability [2][3] - Krause will serve on the Audit Committee and the Litigation Committee of the Board, bringing expertise in corporate strategy, capital allocation, and public company governance [2][3] Group 2: Resignation of Constantine S. Mihas - Constantine ("Dean") S. Mihas has resigned from the Board effective March 16, 2026, due to a reduction in the number of directors certain stockholders can designate [4] - Mihas has been a member of the Board since October 2020 and provided valuable strategic guidance during his tenure [5][6] Group 3: Company Overview - Sotera Health is a leading global provider of end-to-end sterilization solutions, lab testing, and advisory services for the healthcare industry, operating through three businesses: Sterigenics, Nordion, and Nelson Labs [6]

Core Insights - Sotera Health Company reported strong financial results for the fourth quarter and full year of 2025, highlighting solid execution and increased demand for its services [4][7][8] Financial Performance - Fourth-quarter 2025 net revenues rose by 4.6% to $303 million, compared to $290 million in the fourth quarter of 2024, with a constant currency increase of 2.5% [2] - Full-year 2025 net revenues increased by 5.7% to $1.164 billion, up from $1.100 billion in 2024, with a constant currency growth of 5.2% [3][7] - Net income for the fourth quarter was $35 million, or $0.12 per diluted share, compared to $12 million, or $0.04 per diluted share in the same quarter of 2024 [2] - Full-year net income reached $78 million, or $0.27 per diluted share, compared to $44 million, or $0.16 per diluted share in 2024 [3] - Adjusted EBITDA for the fourth quarter increased by 2.7% to $157 million, with a constant currency growth of 0.5% [2] - Full-year adjusted EBITDA rose by 8.2% to $594 million, reflecting a constant currency growth of 7.8% [3] Business Segment Performance - Sterigenics segment reported fourth-quarter 2025 net revenues of $198 million, a 10.6% increase, with segment income of $110 million [6][8] - Nordion's fourth-quarter 2025 net revenues were $50 million, a decrease of 12.3%, attributed to cobalt-60 harvest schedule timing [9][10] - Nelson Labs experienced a 2.3% increase in fourth-quarter net revenues to $55 million, with segment income rising by 1.9% to $18 million [11][12] Management Transition - Effective April 1, 2026, Alex Dimitrief will transition to an advisory role, with Erika Ostrowski promoted to Senior Vice President and General Counsel [5][6] Balance Sheet and Liquidity - As of December 31, 2025, total debt was $2.2 billion, with cash and cash equivalents at $345 million, improving the net leverage ratio to 3.2x from 3.7x in 2024 [13][14] 2026 Outlook - The company anticipates net revenue growth of 5.0% to 6.5% and adjusted EBITDA growth of 5.5% to 7.0% for full-year 2026 [7][15]

Core Viewpoint - Sotera Health Company is set to release its financial results for Q4 and the full year of 2025 on February 24, 2026, before market opening, followed by a conference call to discuss the results and operational highlights [1]. Group 1 - The financial results will cover the period ending December 31, 2025 [1]. - A conference call is scheduled for 9:00 a.m. Eastern Time on the same day to discuss the results [1]. - A live webcast of the conference call will be available on the company's Investor Relations website, with a replay accessible later that day [2]. Group 2 - Sotera Health is recognized as a leading global provider of sterilization solutions, lab testing, and advisory services for the healthcare industry [4]. - The company operates through three business segments: Sterigenics, Nordion, and Nelson Labs [4]. - Sotera Health is dedicated to its mission of safeguarding global health [4].

Core Viewpoint - Sotera Health Company has appointed Richard G. Kyle as a new independent director to its Board of Directors, enhancing its leadership team with his extensive experience in operations and governance [1][2][3]. Group 1: Appointment Details - Richard G. Kyle will serve on the Leadership Development and Compensation Committee and the Nominating and Corporate Governance Committee [1]. - His previous role was as President and CEO of The Timken Company, where he led financial transformation and strategic diversification [2]. - Kyle's selection is based on his experience in leading global operations and strong financial acumen [2][3]. Group 2: Leadership Insights - Michael B. Petras, Jr., Chairman and CEO of Sotera Health, expressed excitement about Kyle's appointment, highlighting his leadership experience as a public company CEO [3]. - Kyle continues to serve on Timken's Board and has been on the Board of Sonoco Products Company since 2015, where he holds multiple committee roles [3]. Group 3: Company Overview - Sotera Health is a global provider of sterilization solutions, lab testing, and advisory services for the healthcare industry [4]. - The company operates through three business segments: Sterigenics, Nordion, and Nelson Labs, with a commitment to safeguarding global health [4].

2026 J.P. Morgan Healthcare Conference Safeguarding Global Health® Michael B. Petras, Jr. Chairman and Chief Executive Officer January 12, 2026 © 2026 Sotera Health Company | All Rights Reserved. Cautionary Note Regarding Forward-Looking Statements and Non-GAAP Financial Measures Unless expressly indicated or the context requires otherwise, the terms "Sotera Health," "Company," "we," "us," and "our" in this presentation refer to Sotera Health Company, a Delaware corporation, and, where appropriate, its subs ...

Core Viewpoint - Sotera Health Company is experiencing solid growth, with revenue expected to exceed $1.16 billion in 2025, marking a year-over-year increase of at least 5.5% [2] Group 1: Company Overview - Sotera Health is a leading global provider of end-to-end sterilization solutions, lab testing, and advisory services for the healthcare industry [6] - The company operates through three business segments: Sterigenics, Nordion, and Nelson Labs [6] - The mission of Sotera Health is to safeguard global health [6] Group 2: Financial Performance - Revenue for 2025 is projected to surpass $1.16 billion, reflecting a growth of at least 5.5% year-over-year or 5.0% on a constant-currency basis [2] - This growth marks over two decades of consecutive year-over-year revenue increases, demonstrating the durability of the company's business model and financial profile [2] - Full-year results and the 2026 outlook will be shared on February 24, 2026 [2] Group 3: Investor Relations - A live webcast of the company's presentation at the J.P. Morgan Healthcare Conference will be available on the Investor Relations section of the company's website [2] - A replay of the presentation will be accessible within 48 hours and archived on the company's website [2]

Core Viewpoint - Sotera Health Company will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, highlighting its role as a leading provider of sterilization solutions and lab testing services for the healthcare industry [1]. Group 1 - Sotera Health is recognized as a global leader in providing mission-critical end-to-end sterilization solutions, lab testing, and advisory services for the healthcare sector [3]. - The company operates through three main business units: Sterigenics®, Nordion®, and Nelson Labs® [3]. - The company is dedicated to its mission of "Safeguarding Global Health®" [3]. Group 2 - A live webcast of the presentation will be accessible on the Investor Relations section of the company's website, with a replay available within 48 hours [2]. - Updates relevant to investors can be found in the Investor Relations section of the company's website [4].

Financial Performance Highlights - Net revenues increased by 9.1% (8.0% on a constant currency basis) to $311312000 in Q3 2025 compared to $285468000 in Q3 2024[31] - Adjusted EBITDA increased by 12.2% (11.2% on a constant currency basis) to $164000000 in Q3 2025 compared to $146000000 in Q3 2024[31] - Adjusted EBITDA margin increased by 147 basis points to 52.7% in Q3 2025[25, 31] - Adjusted EPS increased by $0.09 to $0.26 in Q3 2025[25, 31] - Net Leverage Ratio improved to 3.3x as of September 30, 2025, compared to 3.7x as of December 31, 2024[29, 44] Segment Performance - Sterigenics' revenue increased by 9.8% (8.4% on a constant currency basis) in Q3 2025[33] - Nordion's revenue increased by 22.4% (23.6% on a constant currency basis) in Q3 2025[36] - Nelson Labs' revenue decreased by 5.0% (-6.4% on a constant currency basis) in Q3 2025[39] Liquidity and Capital Deployment - Strong liquidity position of $891000000 as of September 30, 2025, with no outstanding borrowings on the revolving line of credit[29, 43] - Executed $75000000 Term Loan repayment in Q3 2025[29] 2025 Outlook - Full-year 2025 net revenue growth is expected to be between 4.5% and 6.0%[52] - Full-year 2025 Adjusted EBITDA growth is expected to be between 6.75% and 7.75%[52]

Core Insights - Sotera Health Company reported strong financial results for the third quarter and first nine months of 2025, with significant revenue and income growth compared to the previous year [2][3][4]. Financial Performance - Third-quarter 2025 net revenues increased by 9.1% to $311 million, up from $285 million in the third quarter of 2024. On a constant currency basis, the increase was 8.0% [2][8]. - Net income for the third quarter of 2025 was $48 million, or $0.17 per diluted share, compared to $17 million, or $0.06 per diluted share in the same quarter of 2024 [2][8]. - Adjusted EBITDA for the third quarter of 2025 rose by 12.2% to $164 million, with an 11.2% increase on a constant currency basis [2][8]. - For the first nine months of 2025, net revenues grew by 6.2% to $860 million, with net income of $43 million, or $0.15 per diluted share, compared to $32 million, or $0.11 per diluted share in the same period of 2024 [3][8]. Business Segment Performance - Sterigenics segment reported net revenues of $193 million for the third quarter of 2025, a 9.8% increase, with segment income rising by 11.6% to $107 million [5][6]. - Nordion's net revenues increased by 22.4% to $63 million in the third quarter of 2025, with segment income up by 19.9% to $38 million [9][10]. - Nelson Labs experienced a decrease in net revenues by 5.0% to $56 million in the third quarter of 2025, but segment income increased by 1.9% to $19 million [11][12]. Outlook and Guidance - The company reaffirmed its 2025 revenue outlook, projecting growth in the range of 4.5% to 6.0% on a constant currency basis, and raised its Adjusted EBITDA growth outlook to 6.75% to 7.75% [4][16]. - The interest expense range was improved to $154 million to $158 million, and the tax rate applicable to Adjusted Net Income was adjusted to 29.00% to 31.00% [16][17]. Balance Sheet and Liquidity - As of September 30, 2025, Sotera Health had total debt of $2.2 billion and unrestricted cash of $299 million, with a Net Leverage Ratio improved to 3.3x [13][14]. - The company achieved a contractual net leverage target, resulting in a 25 basis point reduction in the interest rate on its First Lien Term Loan facility [14].

Core Viewpoint - Sotera Health Company will release its financial results for the third quarter ended September 30, 2025, on November 4, 2025, before market opening, followed by a conference call to discuss the results and operating highlights [1]. Company Overview - Sotera Health is a leading global provider of mission-critical end-to-end sterilization solutions, lab testing, and advisory services for the healthcare industry [3]. - The company operates through three business segments: Sterigenics, Nordion, and Nelson Labs [3]. - Sotera Health is dedicated to its mission of safeguarding global health [3]. Conference Call Details - The conference call will take place at 9:00 a.m. Eastern Daylight Time on November 4, 2025 [1]. - Participants can join the call by dialing 1-844-481-2916 (toll-free in the U.S.) or 1-412-317-0709 for international calls [2]. - A live webcast of the conference call will be available on the company's website, along with accompanying materials, and a replay will be accessible later that day [2].